4 completed. 2 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Cortria Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pilot Study to Evaluate the Lipid Effects of TRIA-662 TRIA-662, Placebo - Hypertriglyceridemia, Mixed Hyperlipidemia | Phase 2 | Completed | Cortria Corporation | 71 | 2013-12-01 | 2016-01-27 |
| Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions Niaspan, TRIA-662 - Healthy | Phase 1 | Completed | Cortria Corporation | 20 | 2013-03-01 | 2013-08-22 |
| The Safety of a Hypolipidemic Agent in Healthy Normal Volunteers TRIA-662, Placebo - Healthy | Phase 1 | Completed | Cortria Corporation | 20 | 2007-11-01 | 2016-07-26 |
| A Study to Evaluate the Lipid Regulating Effects of TRIA-662 Low Dose TRIA-662, High Dose TRIA-662, Placebo for TRIA-662 - Hyperlipidemia | Phase 2 / Phase 3 | Completed | Cortria Corporation | 211 | 2007-09-01 | 2013-09-13 |
Hyperlipidemias (1) · Hyperlipoproteinemia Type II (1) · Hypertriglyceridemia (1)
N(1)-methylnicotinamide (1) · Niacin (1)
Canada (2)
Eugenio A Cefali, PharmD, PhD. (1) · Jean C Tardif, M.D. (1) · Jean-Claude Tardif, MD (1)